Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
Open Access
- 20 March 2017
- journal article
- research article
- Published by Springer Nature in npj Precision Oncology
- Vol. 1 (1) , 1-5
Abstract
Glioneuronal tumors constitute a histologically diverse group of primary central nervous system neoplasms that are typically slow-growing and managed conservatively. Genetic alterations associated with glioneuronal tumors include BRAF mutations and oncogenic fusions. To further characterize this group of tumors, we collected a cohort of 26 glioneuronal tumors and performed in-depth genomic analysis. We identified mutations in BRAF (34%) and oncogenic fusions (30%), consistent with previously published reports. In addition, we discovered novel oncogenic fusions involving members of the NTRK gene family in a subset of our cohort. One-patient with BCAN exon 13 fused to NTRK1 exon 11 initially underwent a subtotal resection for a 4th ventricular glioneuronal tumor but ultimately required additional therapy due to progressive, symptomatic disease. Given the patient’s targetable fusion, the patient was enrolled on a clinical trial with entrectinib, a pan-Trk, ROS1, and ALK (anaplastic lymphoma kinase) inhibitor. The patient was treated for 11 months and during this time volumetric analysis of the lesion demonstrated a maximum reduction of 60% in the contrast-enhancing tumor compared to his pre-treatment magnetic resonance imaging study. The radiologic response was associated with resolution of his clinical symptoms and was maintained for 11 months on treatment. This report of a BCAN-NTRK1 fusion in glioneuronal tumors highlights its clinical importance as a novel, targetable alteration.Keywords
This publication has 26 references indexed in Scilit:
- New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETsCell, 2016
- Tracking Down Response and Resistance to TRK InhibitorsCancer Discovery, 2016
- Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to CrizotinibJNCI: Journal of the National Cancer Institute, 2015
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerJNCI: Journal of the National Cancer Institute, 2015
- Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted TherapyJNCI: Journal of the National Cancer Institute, 2015
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade GliomasNew England Journal of Medicine, 2015
- NTRK1 Fusion in Glioblastoma MultiformePLOS ONE, 2014
- Recommendations for imaging tumor response in neurofibromatosis clinical trialsNeurology, 2013
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerNature Medicine, 2013
- Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytomaNature Genetics, 2013